Helmholtz Diabetes Center
Institute for Diabetes Research and Metabolic Diseases
The primary research goal of the Institute for Diabetes Research and Metabolic Diseases (IDM) is the individualized prediction of diabetes risk and diabetes prevention and its personalized therapy.
The primary research goal of the Institute for Diabetes Research and Metabolic Diseases (IDM) is the individualized prediction of diabetes risk and diabetes prevention and its personalized therapy.
Director of the Institute of Diabetes Research and Metabolic Diseases (IDM) Helmholtz Munich at the University Hospital Tübingen
View profile
Publications
Semeia, L. ; Zaylaa, A. ; Metaxas, D. ; Nourhashemi, M. ; Mahmoudzadeh, M. ; Birkenfeld, A.L. ; Sippel, K. ; Mediano, P.A.M. ; Preissl, H. ; Wallois, F. ; Frohlich
Neural complexity in preterm infants is predicted by developmental variables.Gallwitz, B. ; Aberle, J. ; Birkenfeld, A.L. ; Kellerer, M. ; Klein, H.H. ; Landgraf, R. ; Müller-Wieland, D. ; Müssig, K. ; Nauck, M.A. ; Siegel, E. ; Szendrödi, J. ; Wiesner, T.
Therapie des Typ-2-Diabetes.Marx-Schütt, K. ; Forst, T. ; Birkenfeld, A.L. ; Zirlik, A. ; Müller-Wieland, D. ; Marx, N.
Diabetes mellitus und Herz.Parhofer, K.G. ; Birkenfeld, A.L. ; Krone, W. ; Lehrke, M. ; Marx, N. ; Merkel, M. ; Marx-Schütt, K. ; Zirlik, A. ; Müller-Wieland, D.
Lipidtherapie bei Patienten mit Diabetes mellitus.Narayan, K.M.V. ; Global Diabetes Forum (2024) (Birkenfeld, A.L.)
Copenhagen Declaration: A transformative vision for global diabetes.Birkenfeld, A.L. ; Perreault, L. ; Schmidt, M.I. ; Schwarz, P.E.H. ; Zoungas, S. ; Gong, Q. ; Chan, J.C.N. ; Mohan, V. ; Tuomilehto, J. ; Bergman, M.
Defining prediabetes remission as a distinct prevention endpoint.Vazquez Arreola, E. ; Gong, Q. ; Hanson, R.L. ; Wang, J. ; Sandforth, L. ; He, S. ; Sandforth, A. ; Qian, X. ; Giacca, M. ; Bornstein, S.R. ; Fritsche, A. ; Stefan, N. ; Preissl, H. ; Gregg, E.W. ; Marx, N. ; Jumpertz von Schwartzenberg, R. ; Li, G. ; Birkenfeld, A.L.
Prediabetes remission and cardiovascular morbidity and mortality: Post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study.Wang, Y. ; Ram, J. ; Bianchi, C. ; Fiorentino, T.V. ; Kim, S.S. ; Kim, J. ; Ryang, S. ; Del Prato, S. ; Sesti, G. ; Sandforth, L. ; Preissl, H. ; Jumpertz von Schwartzenberg, R. ; Stefan, N. ; Fritsche, A. ; Ha, J. ; Birkenfeld, A.L. ; Bergman, M.
Superiority of 1 h plasma glucose vs fasting plasma glucose, 2 h plasma glucose and HbA1c for the diagnosis of type 2 diabetes.Mann, J.F.E. ; Marx, N. ; Deanfield, J.E. ; Emerson, S.S. ; Inzucchi, S.E. ; McGuire, D.K. ; Mulvagh, S.L. ; Pop-Busui, R. ; Poulter, N.R. ; Engelmann, M.D.M. ; Hovingh, G.K. ; Belmar, N. ; Idorn, T. ; Jeppesen, O.K. ; Birkenfeld, A.L. ; Amod, A. ; Mankovsky, B. ; Desouza, C. ; Gorgojo-Martinez, J.J. ; Arechavaleta, R. ; Tu, S.T. ; Buse, J.B.
Impact of oral semaglutide on kidney outcomes in people with type 2 diabetes: Results from the SOUL randomized trial.Sehgal, R. ; Haacke, N. ; Maguolo, A. ; Solari, F.A. ; Jähnert, M. ; Gottmann, P. ; Nilsson, E. ; Vaag, A. ; Fischer-Posovszky, P. ; Werberger, A. ; Birkenfeld, A.L. ; Fritsche, A. ; Häring, H.-U. ; Sickmann, A. ; Vogel, H. ; Ling, C. ; Ouni, M. ; Schürmann, A.
Adipose tissue-derived microRNAs as epigenetic modulators of type 2 diabetes.
Contact
